Last reviewed · How we verify
Disitamab Vedotin Combined With Fruquintinib
Disitamab Vedotin Combined With Fruquintinib is a Small molecule drug developed by Zhongnan Hospital. It is currently FDA-approved.
Disitamab Vedotin combined with Fruquintinib is a marketed therapy developed by Zhongnan Hospital, currently positioned in the oncology segment. The key composition patent expires in 2028, providing a period of exclusivity and potential revenue protection. However, the lack of specified primary indication and key trial results poses a significant risk to its market acceptance and competitive positioning.
At a glance
| Generic name | Disitamab Vedotin Combined With Fruquintinib |
|---|---|
| Sponsor | Zhongnan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression (PHASE4)
- Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disitamab Vedotin Combined With Fruquintinib CI brief — competitive landscape report
- Disitamab Vedotin Combined With Fruquintinib updates RSS · CI watch RSS
- Zhongnan Hospital portfolio CI